Jublia (Efinaconazole) Patent Expiration, LOE Window & CMS Spending

Jublia (Efinaconazole) by Bausch Health: FDA Orange Book LOE 2035-04-25, 2 AB generics, $146.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN203567 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-04-25
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$146.1M
2024 Medicare Part D Spend$118.6M
2024 Medicaid Spend$27.5M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 22.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.